Analysts Set Valeant Pharmaceuticals Intl Inc (VRX) PT at $23.33

Valeant Pharmaceuticals Intl Inc (TSE:VRX) (NYSE:VRX) has been assigned an average rating of “Hold” from the five research firms that are presently covering the stock, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is C$23.33.

Several equities analysts have recently weighed in on VRX shares. TD Securities increased their price objective on Valeant Pharmaceuticals Intl to C$26.00 and gave the company a “hold” rating in a research report on Wednesday, July 12th. Cantor Fitzgerald reissued an “overweight” rating on shares of Valeant Pharmaceuticals Intl in a research report on Thursday, June 29th. Finally, Royal Bank Of Canada reissued a “sector perform” rating and issued a C$25.00 target price on shares of Valeant Pharmaceuticals Intl in a research report on Monday, June 19th.

COPYRIGHT VIOLATION WARNING: “Analysts Set Valeant Pharmaceuticals Intl Inc (VRX) PT at $23.33” was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://ledgergazette.com/2017/10/08/analysts-set-valeant-pharmaceuticals-intl-inc-vrx-pt-at-23-33.html.

In other Valeant Pharmaceuticals Intl news, Director John Paulson sold 24,700 shares of Valeant Pharmaceuticals Intl stock in a transaction that occurred on Wednesday, August 9th. The stock was sold at an average price of C$14.66, for a total value of C$362,102.00. Also, Director Schutter Richard Urbain De acquired 4,900 shares of Valeant Pharmaceuticals Intl stock in a transaction on Monday, August 21st. The stock was purchased at an average cost of C$14.35 per share, for a total transaction of C$70,315.00.

Shares of Valeant Pharmaceuticals Intl (TSE:VRX) traded down 0.87% during trading on Thursday, hitting $18.13. 469,090 shares of the company’s stock were exchanged. The stock’s market cap is $6.32 billion. Valeant Pharmaceuticals Intl has a 1-year low of $11.20 and a 1-year high of $32.50. The stock’s 50-day moving average price is $17.37 and its 200-day moving average price is $17.34.

About Valeant Pharmaceuticals Intl

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) prod

Several equities analysts have recently weighed in on VRX shares. TD Securities increased their price objective on Valeant Pharmaceuticals Intl to C$26.00 and gave the company a “hold” rating in a research report on Wednesday, July 12th. Cantor Fitzgerald reissued an “overweight” rating on shares of Valeant Pharmaceuticals Intl in a research report on Thursday, June 29th. Finally, Royal Bank Of Canada reissued a “sector perform” rating and issued a C$25.00 target price on shares of Valeant Pharmaceuticals Intl in a research report on Monday, June 19th.

COPYRIGHT VIOLATION WARNING: “Analysts Set Valeant Pharmaceuticals Intl Inc (VRX) PT at $23.33” was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://ledgergazette.com/2017/10/08/analysts-set-valeant-pharmaceuticals-intl-inc-vrx-pt-at-23-33.html.

In other Valeant Pharmaceuticals Intl news, Director John Paulson sold 24,700 shares of Valeant Pharmaceuticals Intl stock in a transaction that occurred on Wednesday, August 9th. The stock was sold at an average price of C$14.66, for a total value of C$362,102.00. Also, Director Schutter Richard Urbain De acquired 4,900 shares of Valeant Pharmaceuticals Intl stock in a transaction on Monday, August 21st. The stock was purchased at an average cost of C$14.35 per share, for a total transaction of C$70,315.00.

Shares of Valeant Pharmaceuticals Intl (TSE:VRX) traded down 0.87% during trading on Thursday, hitting $18.13. 469,090 shares of the company’s stock were exchanged. The stock’s market cap is $6.32 billion. Valeant Pharmaceuticals Intl has a 1-year low of $11.20 and a 1-year high of $32.50. The stock’s 50-day moving average price is $17.37 and its 200-day moving average price is $17.34.

About Valeant Pharmaceuticals Intl

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals Intl (TSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply